OTC Viagra too risky, says EMEA
This article was originally published in Scrip
An OTC presentation of Pfizer's Viagra (sildenafil) would be too risky at this point, said the EU's CHMP around the time Pfizer withdrew its application to switch the product to non-prescription status.
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.